2.1 Cardiovascular Therapeutics & Clinical Law

Cardiovascular Therapeutics & Clinical Law

Cardiovascular disease management is a cornerstone of clinical pharmacy practice. For the CPJE, you must master not only the clinical guidelines but also the prescribing and monitoring regulations in California. The role of the pharmacist has expanded significantly in recent years, particularly with the passage of legislation allowing pharmacists to practice at the top of their license. Pharmacists in California who are recognized as Advanced Practice Pharmacists (APh) or those working under a Collaborative Practice Agreement (CPA) can independently initiate, adjust, and discontinue cardiovascular medications, order relevant laboratory tests, and manage complex chronic diseases such as hypertension, heart failure, and dyslipidemia. This section will delve deeply into the evidence-based management of these conditions, the specific nuances of drug therapy, and the legal framework that governs these practices in the state of California.

1. Hypertension Management (ACC/AHA Guidelines)

Hypertension is often referred to as the 'silent killer' because it is usually asymptomatic until it causes significant end-organ damage, such as stroke, myocardial infarction, or chronic kidney disease. The ACC/AHA guidelines redefine hypertension and emphasize a target blood pressure of <130/80 mmHg for most adults. This aggressive target is based on trials like SPRINT, which demonstrated that intensive blood pressure control significantly reduces cardiovascular events and mortality in high-risk patients. Proper measurement technique is critical; blood pressure should be measured after the patient has been resting quietly for at least five minutes, with the arm supported at heart level, and using an appropriately sized cuff.

First-Line Agents

Four classes are considered first-line for primary hypertension, each with its own specific mechanism of action, side effect profile, and contraindications:

• Angiotensin-Converting Enzyme Inhibitors (ACEi) (e.g., lisinopril, enalapril, ramipril). These agents block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, and also prevent the degradation of bradykinin. The accumulation of bradykinin is responsible for the classic dry cough associated with ACE inhibitors. If a patient develops a cough, they should be switched to an ARB. ACE inhibitors are also associated with a risk of angioedema, which can be life-threatening and is more common in Black patients.
• Angiotensin II Receptor Blockers (ARBs) (e.g., losartan, valsartan, olmesartan). These agents block the binding of angiotensin II to the AT1 receptor. They have a similar efficacy and side effect profile to ACE inhibitors but do not cause bradykinin accumulation, making them an excellent alternative for patients who develop a cough on ACE inhibitors.
• Calcium Channel Blockers (CCBs) (e.g., amlodipine, nifedipine, diltiazem, verapamil). These are divided into dihydropyridines (e.g., amlodipine), which primarily affect peripheral vasculature and cause vasodilation, and non-dihydropyridines (e.g., diltiazem, verapamil), which have negative chronotropic and inotropic effects on the heart. Dihydropyridines are preferred for hypertension, while non-dihydropyridines are often used for rate control in atrial fibrillation. A common side effect of dihydropyridines is dose-dependent peripheral edema.
• Thiazide Diuretics (e.g., chlorthalidone, hydrochlorothiazide). These agents inhibit the Na+/Cl- symporter in the distal convoluted tubule. Chlorthalidone is preferred over hydrochlorothiazide based on its longer half-life and proven cardiovascular benefits in clinical trials. Thiazides can cause hypokalemia, hyponatremia, hyperuricemia (which can precipitate gout), and hypercalcemia.

Clinical Pearl: Do not use ACEi and ARBs in combination due to the significantly increased risk of hyperkalemia, hypotension, and acute kidney injury without any added cardiovascular benefit. This combination is universally contraindicated in current guidelines.

Renal Protection in CKD and Diabetes

For patients with Chronic Kidney Disease (CKD) or diabetes with albuminuria (urine albumin-to-creatinine ratio ≥ 300 mg/g), ACEi or ARBs are the unequivocally preferred first-line agents. They reduce intraglomerular pressure by dilating the efferent arteriole to a greater extent than the afferent arteriole, thereby reducing proteinuria and slowing the progression of diabetic and non-diabetic nephropathy. When initiating an ACEi or ARB, a mild increase in serum creatinine (up to 30%) is acceptable and expected; however, if the creatinine increases by more than 30%, the medication should be discontinued or the dose reduced, and renal artery stenosis should be suspected.

2. Heart Failure with Reduced Ejection Fraction (HFrEF)

Heart failure is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood. HFrEF is defined as an ejection fraction ≤ 40%. Guideline-Directed Medical Therapy (GDMT) for HFrEF has undergone a paradigm shift and now includes four foundational pillars that should be initiated as early as possible and titrated to target doses to optimally reduce mortality and morbidity.

1. Renin-Angiotensin System Inhibitors: The Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan is currently the preferred agent over ACEi or ARBs. Neprilysin is an enzyme that degrades natriuretic peptides, bradykinin, and other vasoactive peptides. By inhibiting neprilysin, sacubitril increases these beneficial peptides, causing vasodilation and diuresis. Because neprilysin inhibition also increases bradykinin, sacubitril must be combined with an ARB (valsartan) rather than an ACEi to minimize the risk of angioedema. When switching a patient from an ACEi to an ARNI, a mandatory 36-hour washout period is legally and clinically required to prevent life-threatening angioedema.
2. Evidence-Based Beta-Blockers: Not all beta-blockers are created equal. Only three are approved and proven to reduce mortality in HFrEF: metoprolol succinate (extended-release), carvedilol, and bisoprolol. These should only be initiated when the patient is euvolemic (free of congestion). Abrupt discontinuation can lead to rebound tachycardia and exacerbation of heart failure.
3. Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone or eplerenone reduce mortality and hospitalizations. They block the deleterious effects of aldosterone on the heart, including fibrosis and remodeling. Strict monitoring of potassium and renal function is legally and clinically mandated. MRAs should not be initiated if serum potassium is > 5.0 mEq/L or if creatinine clearance is < 30 mL/min.
4. SGLT2 Inhibitors: Dapagliflozin or empagliflozin are the newest additions to GDMT. Originally developed for diabetes, these agents profoundly reduce cardiovascular mortality and heart failure hospitalizations independently of their glucose-lowering effects. They are recommended for all HFrEF patients with or without type 2 diabetes. Pharmacists must counsel on the risks of genital mycotic infections and euglycemic diabetic ketoacidosis (DKA).

3. Dyslipidemia and Statin Benefit Groups

Cholesterol management is guided by the ACC/AHA guidelines, which eschew specific LDL-C targets in favor of categorizing patients into four statin benefit groups to determine the appropriate statin intensity. Statins (HMG-CoA reductase inhibitors) reduce hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL from the bloodstream.

Statin Benefit Groups

1. Clinical ASCVD: Includes patients with a history of acute coronary syndrome (ACS), myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral artery disease. These patients require a High-intensity statin.
2. Primary elevation of LDL-C ≥ 190 mg/dL: These patients often have familial hypercholesterolemia and require a High-intensity statin.
3. Diabetes (Age 40-75) with LDL-C 70-189 mg/dL: Requires at least a Moderate-intensity statin. If the patient has multiple ASCVD risk factors, a high-intensity statin is indicated.
4. Primary prevention (Age 40-75) with ASCVD risk ≥ 7.5%: The 10-year ASCVD risk calculator is used. Patients with a risk ≥ 7.5% should be started on a Moderate to high-intensity statin after a risk discussion.

High vs. Moderate Intensity

• High-Intensity: Lowers LDL-C by ≥ 50%. The only two options are Atorvastatin 40-80 mg and Rosuvastatin 20-40 mg.
• Moderate-Intensity: Lowers LDL-C by 30-49%. Options include Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, and Pravastatin 40-80 mg.

Safety Monitoring: Monitor for statin-associated muscle symptoms (SAMS), ranging from myalgia to life-threatening rhabdomyolysis. Routine LFT monitoring is no longer recommended unless the patient develops symptoms of hepatotoxicity (jaundice, fatigue, dark urine). Simvastatin 80 mg should never be initiated in new patients due to a high risk of myopathy, particularly when interacting with CYP3A4 inhibitors.

4. Antiplatelet & Anticoagulant Therapy

Dual Antiplatelet Therapy (DAPT)

DAPT consists of aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor). The duration depends heavily on the indication. For patients who undergo Percutaneous Coronary Intervention (PCI) with a stent, DAPT is universally required. Post-ACS, DAPT is recommended for at least 12 months, regardless of whether a bare-metal stent (BMS) or drug-eluting stent (DES) was placed. Clopidogrel requires conversion to its active metabolite by CYP2C19; pharmacogenomic testing or alternative therapy (ticagrelor/prasugrel) is recommended in known poor metabolizers.

DOACs vs. Warfarin

Direct Oral Anticoagulants (DOACs) include direct thrombin inhibitors (dabigatran) and Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban). DOACs are definitively preferred over warfarin for non-valvular atrial fibrillation and VTE treatment due to predictable pharmacokinetics, fewer drug-food interactions, and no need for routine INR monitoring. However, warfarin remains the anticoagulant of choice for patients with mechanical heart valves and moderate-to-severe mitral stenosis. DOAC doses must be rigorously adjusted for renal function, and edoxaban is uniquely contraindicated in patients with too good of renal function (CrCl > 95 mL/min) due to reduced efficacy.

Reversal Agents

In the event of life-threatening bleeding or need for emergent surgery, the following specific reversal agents are used:

• Warfarin: Vitamin K (phytonadione) and Kcentra (4-factor Prothrombin Complex Concentrate). Vitamin K can be given orally or via slow IV infusion (to avoid anaphylaxis). SQ or IM administration is not recommended.
• Dabigatran: Idarucizumab (Praxbind). This is a monoclonal antibody fragment that binds dabigatran with high affinity.
• Apixaban / Rivaroxaban: Andexanet alfa (Andexxa). This acts as a decoy receptor for Factor Xa inhibitors.

California Pharmacy Law Integration

In California, pharmacists have significant prescribing and furnishing authority. Under B&P Code 4052.2, a pharmacist may initiate, adjust, and monitor anticoagulant therapy, including ordering relevant lab tests like INRs, under a Collaborative Practice Agreement (CPA) with a prescriber. Furthermore, the California State Board of Pharmacy requires strict adherence to consultation laws; any new prescription or change in dose (which happens frequently with warfarin titration) mandates verbal consultation by the pharmacist. This applies heavily to DOAC and warfarin therapy due to their high-risk nature.